Massachusetts Neuroscience Consortium Now Accepting Applications

September 25, 2012

The Massachusetts Life Sciences Center (MLSC) is pleased to announce the launch of the first Request for Proposals (RFP) funded by seven global biopharmaceutical  companies that comprise the Massachusetts Neuroscience Consortium (the "Consortium"). The Consortium, the formation of which was announced in June at the Bio International Convention, will fund pre-clinical neuroscience research at Massachusetts academic and research institutions. Participating companies includeAbbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals (Consortium Members). Each of the Consortium Members has contributed to the total available project funding of $1,750,000.

The Consortium is a pioneering new model that is designed to accelerate significant breakthroughs in neuroscience and is founded on the belief that companies will accelerate such breakthroughs by working together. Consortium Members have pooled their resources to fund the identification and validation of novel targets for the symptomatic treatment and modification of chronic and debilitating neurological diseases. Proposals are being solicited within the primary focus areas of Alzheimer's Disease, Multiple Sclerosis, Neuropathic Pain, and Parkinson's Disease. All proposals must be anchored in recognized human disease genetics and pathophysiology, or within pathways of known relevance to human disease, and should be translational, rather than exploratory.

All Massachusetts academic and research institutions are eligible to apply for grant funding through the Consortium.  There is no limit to the number of applications that may be submitted from any one institution. Applicants will submit research projects to be reviewed by the members of the Consortium.

The MLSC will administer the program. Interested applicants must apply via the MLSC's website:  www.masslifesciences.com/neuroscience.html.

The deadline for 2-page Pre-Proposal applications is November 16, 2012 at noon.

Applicants that are invited to proceed to the next stage will be required to submit a Full Proposal which will be due on January 15, 2013. Consortium Members will then determine which applicants will be finalists and invited to present to Consortium Members and the Consortium's Scientific Advisory Board on February 19, 2013.

If you have questions about the program after you have reviewed the materials on our website, please send us an e-mail at:  neuroscience@masslifesciences.com or feel free to reach out to Beth Nicklas at 781-373-7715.

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Upcoming Events email!
For Email Marketing you can trust

MassBio